"Designing Growth Strategies is in our DNA"
The global tuberculosis (TB) diagnostics market size was valued at USD 1.71 billion in 2021 and is projected to grow from USD 2.07 billion in 2022 to USD 3.13 billion by 2029, exhibiting a CAGR of 6.1% during the forecast period. Based on our analysis, the global market exhibited a decline of -21.5% in 2020 as compared to 2019. The global COVID-19 pandemic has been unprecedented and staggering, with tuberculosis diagnostics experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels.
Tuberculosis is a contagious disorder caused by a type of bacteria called Mycobacterium tuberculosis. The infection usually attacks the patient’s lungs. The infection can also attack other body parts such as the brain and spine. Tuberculosis diagnosis can be performed through skin tests and blood tests. The increasing prevalence of this disorder has been increasing the need for accurate and efficient diagnostic tests to control its spread. This factor is expected to significantly boost the demand for tuberculosis diagnostics in the coming years.
The tuberculosis diagnostics market growth is attributed to increasing TB incidences, growing awareness about the disease, and increased demand for tuberculosis diagnostics to control the disease burden. Furthermore, the rising focus of the market players on the approval and commercialization of their products for TB diagnoses has also been boosting the market growth.
Declining Diagnosis of Tuberculosis Negatively Impacted Market Growth
The COVID-19 pandemic resulted in a decline in the demand for tuberculosis diagnostic products during the pandemic. This factor was due to the significant decline in patient volumes for TB diagnosis. The global market witnessed a decline in its growth by -21.5% in 2020 compared to the prior year.
The COVID-19 pandemic caused a decline in the rate of TB testing across the high-burden regions of the global market. Despite the strong infectious nature of the disease, during the initial days of the pandemic, the resources devoted to tuberculosis diagnosis programs were diverted to fight against the coronavirus pandemic.
As the cases attributable to COVID-19 increased worldwide, in 2020, various health workers, testing machines, laboratories, and health centers were diverted from tuberculosis care to COVID-19 care.
The market players also experienced a decline in revenues due to decreased sales of their TB diagnosis instruments and consumables during the pandemic. For instance, bioMérieux SA’s immunoassay business segment, which includes tuberculosis diagnostics, witnessed a decline of -9.7% in 2020 compared to the prior year.
However, there was a significant rebound for the market in 2021, as TB testing increased significantly, especially in the high-burden countries. As lockdown restrictions were lifted, the testing levels for tuberculosis increased and are likely to gain similar levels of procedural volume during the forecast period as it was before the pandemic.
Request a Free sample to learn more about this report.
Increased Public-Private Partnerships to Boost the Market Growth
In the past few years, there has been an increase in public-private partnerships. The public-private partnerships have a strong positive impact on the market as they contribute to the expansion of tuberculosis diagnosis utilizing the international healthcare standards. In the South Asia region, the private health sector provides a significant proportion of diagnostics for diseases such as tuberculosis as per government initiatives. Furthermore, government initiatives for increasing awareness regarding the disease and its early diagnosis are also expected to boost the market.
Developments in terms of private-public partnerships are expected to positively impact the TB diagnostics market. In 2018, GAIL India launched an innovative TB-Free Pata Project, which encompasses aspects such as awareness, screening, diagnosis, and nutritional support in India. The objective of the project is to promote early diagnosis and treatment adherence. Such public-private partnerships are driving the growth of the global market.
Favorable Government Policies to Surge the Demand for Tuberculosis (TB) Diagnostics
Governments have increased the policies for the diagnosis of tuberculosis to reduce the tuberculosis burden globally. The demand for diagnosis is expected to grow over the next few years, as there is a strong increase in the levels of awareness amongst countries regarding the severity of the disease. Many countries have emphasized the development of policies to increase the diagnosis rates for tuberculosis.
Factors, such as the high incidence of tuberculosis in high-burden countries and increasing demand for TB testing, further increase the need for government policies and regulations to improve tuberculosis diagnosis rates. Furthermore, the rising awareness in high TB burden countries where the key focus is to reduce tuberculosis cases is expected to strongly propel the sales of TB diagnostics in the coming years.
Tuberculosis incidence has been growing at a faster pace every year worldwide. For instance, as per the India TB report 2022, the total number of incident TB patients, including both new & relapse cases notified during 2021 was approximately 1.9 million, which was 19.0% higher than 2020. Due to such high TB incidence rates, governments from different countries have increased their focus on improving their healthcare expenditure for TB diagnosis and care.
To reduce the incidence of TB, the government has been releasing policies, leading to strong growth prospects in the global market.
Such policies and government initiatives are expected to fuel the market growth during the forecast period.
Rising Incidence of Tuberculosis in High Burden Countries to Boost Market Growth
One of the most critical drivers that are positively impacting the market's growth is the significant increase in the incidence of this disease across emerging countries. For instance, over the past few decades, there has been a surge in patient population suffering from tuberculosis. This factor led to increased demand for research into effective diagnostic technologies for improved patient outcomes and greater accuracy in the diagnosis of these conditions.
Such strong incidence rates and increasing demand for TB diagnosis are expected to propel the global market growth in the coming years.
Limitations of Existing Tuberculosis (TB) Diagnostics to Impede Market Growth
Despite a critical and increased need for advanced diagnostics technologies for these diseases, there are a few limitations that may hamper the market growth in the forecast period.
For instance, certain technical complexities associated with tuberculosis diagnostics can act as a major restraining factor for the market during the forecast period. The higher degree of technical challenges in developing these diagnostic technologies is one of the key reasons limiting the overall market growth.
Such technical limitations associated with tuberculosis diagnostics are expected to hamper the market growth during the forecast timeframe.
To know how our report can help streamline your business, Speak to Analyst
New Product Launches to Accelerate the Growth of Rapid Molecular Diagnostics Segment to Dominate
On the basis of type, the market is segmented into culture-based diagnostics, sputum smear microscopy, rapid molecular diagnostics, and others.
The rapid molecular diagnostics segment dominated the market in 2021 and is estimated to hold a significant market share throughout the forecast period. The segment's growth is attributed to the efficiency and accuracy associated with rapid molecular diagnostics for TB diagnosis. New product launches in the rapid molecular diagnostics segment are also anticipated to further drive the segment's growth during the forecast period.
Furthermore, the culture-based diagnostics segment is expected to grow substantially during the forecast period. The segment's growth is attributed to rising TB incidence, which is increasing the demand for efficient, technologically advanced diagnostics.
Strong Presence of Diagnostic Laboratories to Boost Segment’s Growth
Based on end-user, the market is bifurcated into diagnostic laboratories and hospitals. The diagnostic laboratories segment accounted for a significant share of the market. The segment's growth is due to the strong presence of diagnostic laboratories worldwide. Moreover, an increasing trend of TB diagnosis being conducted in these diagnostic laboratories is responsible for the segment’s growth.
The hospitals segment is estimated to grow at a significant CAGR during the forecast period owing to the substantial number of tuberculosis diagnosis procedures conducted in hospitals.
North America Tuberculosis (TB) Diagnostics Market Size, 2021 (USD Billion)
To get more information on the regional analysis of this market, Request a Free sample
The market size in North America stood at USD 0.49 billion in 2021. The robust share of the region is due to the increasing prevalence of TB, which has been boosting the number of TB diagnosis being conducted in the region. Moreover, the strong presence of market players in this region is expected to contribute to the market growth during the forecast period.
Europe captured a substantial market share in 2021. The segment's growth is attributable to the increasing demand for TB diagnostics such as rapid molecular diagnostics in Europe and initiatives undertaken by the European government agencies to increase the number of diagnostic laboratories in key countries such as the U.K.
Asia Pacific is estimated to witness a significant CAGR in the market during the forecast period. The improvement in healthcare infrastructure in Asian countries, the high burden of TB disease in this region, and the increasing demand among individuals for better treatment outcomes are driving the market growth rate in the Asia Pacific.
Latin America and the Middle East & Africa regions are expected to expand at comparatively low CAGR during the forecast period. These regions are expected to witness substantial growth during the forecast period owing to increasing number of companies penetrating in these regions to expand their geographic presence.
Market Players with Strong Focus on Expansion of Tuberculosis Diagnostics Portfolio to Hold Major Market Share
bioMérieux SA, F. Hoffmann-La Roche Ltd., and Abbott are the prominent players in the market and accounted for a significant tuberculosis diagnostics market share in 2021.
bioMérieux SA dominated the market in 2021. The company’s market dominance is due to its strong product portfolio for test types such as IGRA tests and continuous novel product launches in the market. The company has a considerably strong product portfolio, including VIDAS TB-IGRA.
Other significant players, including Cepheid (Danaher), Thermo Fisher, and Qiagen are increasing their emphasis on research and development activities for the development of innovative diagnostics and to strengthen their presence in the global market.
An Infographic Representation of Tuberculosis (TB) Diagnostics Market
To get information on various segments, share your queries with us
The research report provides a detailed competitive landscape. It focuses on key points such as new product launches in the market. Additionally, it includes the incidence of tuberculosis and key industry developments such as partnerships, mergers, and acquisitions. Furthermore, the report covers a regional analysis of different segments, company profiles of key market players, and the impact of COVID-19 on the market. The report consists of qualitative and quantitative insights contributing to the market's growth.
ATTRIBUTE | DETAILS |
Study Period | 2018-2029 |
Base Year | 2021 |
Estimated Year | 2022 |
Forecast Period | 2022-2029 |
Historical Period | 2018-2020 |
Unit | Value (USD Billion) |
Segmentation | By Type
|
By End-user
| |
By Geography
|
Fortune Business Insights says that the global market stood at USD 1.71 billion in 2021 and is projected to reach USD 3.13 billion by 2029.
The market is expected to exhibit a CAGR of 6.1% during the forecast period (2022-2029).
The rapid molecular diagnostics segment is set to lead the market by type.
The key factors driving the market are favorable government policies, high incidence of tuberculosis, and increasing initiatives by market players for the development of technologically advanced products
bioMerieux SA, F. Hoffmann-La Roche Ltd., and Abbott are the top players in the market.